A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Phase 1/2 Completed
281 enrolled 44 charts
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma
Phase 1/2 Completed
20 enrolled
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.
Phase 1/2 Completed
28 enrolled
MIZAR-002
Phase 1/2 Completed
18 enrolled
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
Phase 1/2 Completed
26 enrolled 27 charts
KEYMAKER-U02
Phase 1/2 Completed
56 enrolled
ConsortiumIO
Phase 1/2 Completed
56 enrolled 11 charts
KEYMAKER-U02
Phase 1/2 Completed
146 enrolled
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Phase 1/2 Completed
89 enrolled 24 charts
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Phase 1/2 Completed
61 enrolled
CRIRIN
Phase 1/2 Completed
19 enrolled
KEYMAKER-U02
Phase 1/2 Completed
100 enrolled
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Phase 1/2 Completed
29 enrolled 15 charts
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
87 enrolled 22 charts
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Phase 1/2 Completed
307 enrolled 27 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
Phase 1/2 Completed
110 enrolled 27 charts
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma
Phase 1/2 Completed
33 enrolled
RTA 408 Capsules in Patients With Melanoma - REVEAL
Phase 1/2 Completed
41 enrolled 15 charts
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Phase 1/2 Completed
243 enrolled 26 charts
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)
Phase 1/2 Completed
191 enrolled 26 charts
DONIMI
Phase 1/2 Completed
44 enrolled
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
Phase 1/2 Completed
36 enrolled
Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Phase 1/2 Completed
48 enrolled 13 charts
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Phase 1/2 Completed
34 enrolled 14 charts
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Phase 1/2 Completed
132 enrolled
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
Phase 1/2 Completed
27 enrolled 16 charts
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Phase 1/2 Completed
74 enrolled
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Phase 1/2 Completed
79 enrolled
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Phase 1/2 Completed
12 enrolled
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Phase 1/2 Completed
13 enrolled
CombiRT
Phase 1/2 Completed
10 enrolled
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
Phase 1/2 Completed
10 enrolled 10 charts
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Phase 1/2 Completed
26 enrolled 13 charts
A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma
Phase 1/2 Completed
24 enrolled 18 charts
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Phase 1/2 Completed
26 enrolled 47 charts
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Phase 1/2 Completed
6 enrolled 12 charts
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Phase 1/2 Completed
5 enrolled 10 charts
Mel66
Phase 1/2 Completed
22 enrolled
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Phase 1/2 Completed
217 enrolled 27 charts
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
Phase 1/2 Completed
26 enrolled 8 charts
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
MEL60
Phase 1/2 Completed
50 enrolled 13 charts
Mel-65
Phase 1/2 Completed
33 enrolled
CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
Phase 1/2 Completed
140 enrolled 16 charts
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
Phase 1/2 Completed
90 enrolled
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Phase 1/2 Completed
96 enrolled
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Phase 1/2 Completed
61 enrolled 14 charts